NEW YORK, July 8 - Invitrogen has paid Genicon Sciences $2 million for the rights to its nanoparticle signal generation and detection technology and products, the companies said today.
Genicon, of San Diego, uses gold and silver particles in its technology, Resonance Light Scattering, or RLS, and has used it for detection of proteins and nucleic acids, including in DNA and protein microarrays. Genicon launched a DNA microarray toolkit in July 2002, and has co-distributed the toolkit with Qiagen.
Invitrogen said it plans to continue the co-distribution agreement with Qiagen for the DNA microarray toolkit, but will retain the exclusive worldwide commercialization rights for protein and other applications of RLS.
"The extraordinary sensitivity of the RLS technology allows researchers to detect low abundance molecules directly and to better monitor biological interactions such as nucleic acid hybridization," John Carrino, Invitrogen's VP for Research and Development, said in a statement. "The demand for highly-sensitive detection technologies has grown dramatically in recent years as rare targets are implicated in disease and the use of small, micro-dissected tissue samples becomes more prevalent in research."
Invitrogen is headquartered in Carlsbad, Calif.